Ascletis Pharma submits Investigational New Drug (IND) applications to the FDA for two new obesity drugs
July 9, 2026
Source: drugdu
31
Recently, Ascletis Pharma announced that it has recently submitted two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA): ASC36, a next-generation peptide amylin receptor agonist administered once monthly to quarterly, and ASC36_35FDC, a once-monthly injectable combination of ASC36 and the peptide GLP-1R/GIPR agonist ASC35, for the treatment of obesity.
According to relevant data, the overweight rate among adults in my country is about 34.3%, and the obesity rate is about 16.4%; the overweight rate among children and adolescents aged 6 to 17 is 11.1%, and the obesity rate is 7.9%, indicating that the overall situation is still not optimistic.
https://mp.weixin.qq.com/s/Vt-YLF5ncLZAxzwrngG75A
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Fengtou News | Highlight Pharmaceuticals’ Ganoxitinib Receives Breakthrough Therapy Designation from CDE July 9, 2026
- 【Company Recommendation】Emeishan Hongsen Biopharmaceutical Co., Ltd. June 26, 2026
- China’s first ADC (Advanced Dioxide Doppler) to be submitted for market approval June 25, 2026
- Sanofi’s second autoimmune BTK inhibitor approved for marketing June 25, 2026
- Qingfeng Pharmaceutical’s apalutamide tablets have been approved, adding another powerful tool to the field of anti-tumor therapy June 25, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
